secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0000950170-22-021847
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics Q3 net loss $142.3M, cash $896M; FDA AdCom Dec 13 for omecamtiv mecarbil
--------------------------------------------------------------------------------

- Net loss of $142.3M ($1.52/share) vs $76.1M ($0.95) in Q3 2021; revenue $2.5M, down from $5.4M.
- Cash, equivalents and investments $896.2M; net proceeds of $523.6M from 3.50% convertible notes due 2027.
- FDA Advisory Committee to review omecamtiv mecarbil NDA on Dec 13, 2022; PDUFA target Feb 28, 2023.
- SEQUOIA-HCM (aficamten Phase 3) enrollment ongoing; results expected in 2H 2023.
- COURAGE-ALS (reldesemtiv Phase 3) continues after first interim analysis; enrollment to complete 1H 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000095017022021847/0000950170-22-021847-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000095017022021847/cytk-20221103.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-021847

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer